Verisante Technology, Inc. operates as a medical device company engaged in the development of innovative systems for the early detection of cancer. It develops and offers a range of compact, non?invasive cancer detection devices for many of the most common cancers, including gastro?intestinal, colorectal and cervical cancers. The Company's Verisante Aura series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. Other product offered by the company includes Verisante Core series and Authenticare- a pre-production prototype of a pharmaceutical tablet analyzer for the authentication of solid dosage pharmaceuticals. Verisante Technology, Inc. is based in Vancouver, British Columbia.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-0.07M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -3741.21% |
| Return on Assets (Trailing 12 Months) | -510.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.00 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $0.00 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 43.94M |
| Free Float | -- |
| Market Capitalization | $0.22M |
| Average Volume (Last 20 Days) | 0.00 |
| Beta (Past 60 Months) | 19.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |